Phathom Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for gastrointestinal diseases. The company develops its products based on vonozopran, an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. Its products under development include VOQUEZNA, which has completed its Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and its Phase II clinical trials for the as-needed dosing for active heartburn episodes; and VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, which have completed the Phase III clinical trials for the eradication of Helicobacter pylori infection. The company has the rights in the United States, Europe, and Canada for P-CAB. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Phathom Pharmaceuticals Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Climb Bio (CLYM), Humacyte (HUMA) and Phathom Pharma...

Analysts Offer Insights on Healthcare Companies: Climb Bio (CLYM), Humacyte (HUMA) and Phathom Pharmaceuticals (PHAT)

Phathom Pharmaceuticals ( ($PHAT) ) has issued an update. On May 19, 2026, Phathom Pharmaceuticals held its 2026 Annual Meeting of Stockholders, at...

Phathom Shareholders Reaffirm Board, Pay and Auditor

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NexGel Inc (NXGL) and Phathom Pharmaceuticals (PHAT)...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PHAT	$11.10	-2.03%	833.41K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PHAT	$11.10	-2.0%	833.41K
3
4
5
6

PHAT

PHAT

Get Phathom Pharmaceuticals Inc. Data in Excel

Get Phathom Pharmaceuticals Inc. Data in Excel